In summary, the novel therapeutic agents called licMABs promoted NK cell-mediated cytotoxicity on CD33 and CD47 double positive AML cell lines and primary, patient-derived AML cells and did not trigger depletion of CD33 negative, CD47 positive cells. This evidence concerns the gene CD33 and acute myeloid leukemia.